Macrocure says CureXcell likely to fail in Phase III

Macrocure Ltd. (NASDAQ:MCUR) said a futility analysis showed CureXcell was unlikely to meet the primary endpoint of the Phase III MC-105 trial to treat venous leg ulcers.

The company said an independent DSMB determined CureXcell was unlikely to increase the proportion of subjects with superior time to 100% wound closure at 12 weeks and sustained complete closure for four additional weeks (p≤0.05). ...